1 enrolling by invitation. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Enrolling by invitation 1 |
Follow Nanfang Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia Mineralocorticoid Receptor Antagonists(MRAs), Blank control - Hypertension, Hyperaldosteronaemia | Phase 4 | Enrolling by invitation | Nanfang Li | 8000 | 2023-04-16 | 2023-04-18 |
Hyperaldosteronism (1) · Hypertension (1)
Mineralocorticoid Receptor Antagonists (1)
China (1)
PMID 25052724, PMID 26414968, PMID 28822744, PMID 29129575, PMID 30077215, PMID 32418495